Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Lipella Reveals Receipt Of FDA Type-C Meeting Guidance Regarding LP-10 (Liposomal Tacrolimus) Clinical Program; Plans To Advance Lead Product Candidate To Phase 2b

Author: Benzinga Newsdesk | May 21, 2024 08:05am

Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024.

Lipella's Chief Medical Officer, Dr. Michael Chancellor, stated, "We can now proceed with the confidence that our Phase 2b study design can successfully meet its regulatory objectives. This clarity significantly advances our value proposition."

Posted In: LIPO